Bicuspid aortic valve disease is currently a challenge for Transcatheter Aortic Valve Implantation (TAVR). Bicuspid disease has so far been an exclusion criterion in randomized TAVR trials. Issues with severe bicuspid and TAVR include significant peri-prosthetic regurgitation and device malposition.
This live case will feature a mechanically expandable transcatheter heart valve with complete re-positionability and a sealing skirt. These features will be discussed in the context of bicuspid valve disease treatment.
Dr Nicolas M. Van Mieghem obtained his medical degree and cardiology degree at the Catholic University of Leuven, Belgium. After subsequent Fellowships in interventional cardiology in Ziekenhuis Oost-Limburg Genk, Belgium, Lenox Hill Hospital, New York, USA and Erasmus Medical Center, Rotterdam, the Netherlands, he joined the department of interventional cardiology in the Thoraxcenter, Erasmus MC as a senior staff member in February 2010. He is involved in the percutaneous coronary interventions program and has a particular focus on transcatheter heart valve interventions. He obtained the degree of PhD based upon his research in transcatheter valve therapies. So far he has published and co-authored over 160 scientific papers in peer-reviewed journals. Dr Van Mieghem is principle investigator and steering committee member in multiple ongoing international trials evaluating various transcatheter valve technologies. He is a Fellow of the European Society of Cardiology (FESC) and is currently Medical Director of the department of Interventional cardiology in the Thoraxcenter, Erasmus MC, Rotterdam.
This case is supported by Simple Education
This case is to inform and educate cardiologists on: